| Published Application/Species/Sample/Dilution | Reference |
|---|
- immunohistochemistry - paraffin section; rat; 1:50; loading ...; fig s1b
| Inoue T, Kokubo T, Daino K, Yanagihara H, Watanabe F, Tsuruoka C, et al. Interstitial chromosomal deletion of the tuberous sclerosis complex 2 locus is a signature for radiation-associated renal tumors in Eker rats. Cancer Sci. 2020;111:840-848 pubmed publisher |
- immunohistochemistry; human; 1:50; loading ...; fig 1h
| Machado L, Alvarenga A, da Silva F, Roffe M, Begnami M, Torres L, et al. Overexpression of mTOR and p(240-244)S6 in IDH1 Wild-Type Human Glioblastomas Is Predictive of Low Survival. J Histochem Cytochem. 2018;66:403-414 pubmed publisher |
- immunohistochemistry; human; 1:100; tbl 2
| Menter T, Dickenmann M, Juskevicius D, Steiger J, Dirnhofer S, Tzankov A. Comprehensive phenotypic characterization of PTLD reveals potential reliance on EBV or NF-κB signalling instead of B-cell receptor signalling. Hematol Oncol. 2017;35:187-197 pubmed publisher |
- western blot; human; 1:1000
| Liu C, Lin S, Hsu H, Yang S, Lin C, Yang M, et al. Suspension survival mediated by PP2A-STAT3-Col XVII determines tumour initiation and metastasis in cancer stem cells. Nat Commun. 2016;7:11798 pubmed publisher |
- immunohistochemistry - paraffin section; human; 1:100; loading ...; fig 1a
| Hoefflin R, Lahrmann B, Warsow G, Hübschmann D, Spath C, Walter B, et al. Spatial niche formation but not malignant progression is a driving force for intratumoural heterogeneity. Nat Commun. 2016;7:ncomms11845 pubmed publisher |
- western blot; human; loading ...; fig 4a
| Lin T, Chang Y, Lee S, Campbell M, Wang T, Shen S, et al. REST reduction is essential for hypoxia-induced neuroendocrine differentiation of prostate cancer cells by activating autophagy signaling. Oncotarget. 2016;7:26137-51 pubmed publisher |
- western blot; human; 1:1000; fig 9
| E L, Swerdlow R. Lactate's effect on human neuroblastoma cell bioenergetic fluxes. Biochem Pharmacol. 2016;99:88-100 pubmed publisher |
- immunohistochemistry - paraffin section; human; 1:100
| McBryan J, Fagan A, McCartan D, Bane F, Varešlija D, Cocchiglia S, et al. Transcriptomic Profiling of Sequential Tumors from Breast Cancer Patients Provides a Global View of Metastatic Expression Changes Following Endocrine Therapy. Clin Cancer Res. 2015;21:5371-9 pubmed publisher |
- immunohistochemistry; human; 1:50; loading ...; fig 1f
| Choi E, Byeon S, Kim S, Lee H, Kwon H, Ahn H, et al. Implication of Leptin-Signaling Proteins and Epstein-Barr Virus in Gastric Carcinomas. PLoS ONE. 2015;10:e0130839 pubmed publisher |
- immunohistochemistry; human; 1:50
| Mundim F, Pasini F, Brentani M, Soares F, Nonogaki S, Waitzberg A. MYC is expressed in the stromal and epithelial cells of primary breast carcinoma and paired nodal metastases. Mol Clin Oncol. 2015;3:506-514 pubmed |
- immunohistochemistry - paraffin section; human; 1:50
| Tasioudi K, Sakellariou S, Levidou G, Theodorou D, Michalopoulos N, Patsouris E, et al. Immunohistochemical and molecular analysis of PI3K/AKT/mTOR pathway in esophageal carcinoma. APMIS. 2015;123:639-47 pubmed publisher |
- immunohistochemistry; rat; 1:200
| Chen W, Huang S, Liao C, Sung C, Chen J, Wen Z. The use of the antimicrobial peptide piscidin (PCD)-1 as a novel anti-nociceptive agent. Biomaterials. 2015;53:1-11 pubmed publisher |
- immunohistochemistry - frozen section; rat; 1:200
| Huang S, Sung C, Chen W, Chen C, Feng C, Yang S, et al. Involvement of phosphatase and tensin homolog deleted from chromosome 10 in rodent model of neuropathic pain. J Neuroinflammation. 2015;12:59 pubmed publisher |
- immunohistochemistry - paraffin section; mouse; fig 2
| Li X, Tao J, Cigliano A, Sini M, Calderaro J, Azoulay D, et al. Co-activation of PIK3CA and Yap promotes development of hepatocellular and cholangiocellular tumors in mouse and human liver. Oncotarget. 2015;6:10102-15 pubmed |
- immunohistochemistry - paraffin section; human; fig 7
- western blot; human; fig 4
| Chen Y, Wei M, Wang C, Lee H, Pan S, Gao M, et al. Dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor is an effective radiosensitizer for colorectal cancer. Cancer Lett. 2015;357:582-90 pubmed publisher |
| Gargalionis A, Korkolopoulou P, Farmaki E, Piperi C, Dalagiorgou G, Adamopoulos C, et al. Polycystin-1 and polycystin-2 are involved in the acquisition of aggressive phenotypes in colorectal cancer. Int J Cancer. 2015;136:1515-27 pubmed publisher |
- western blot; mouse; 1:1000
| E L, Burns J, Swerdlow R. Effect of high-intensity exercise on aged mouse brain mitochondria, neurogenesis, and inflammation. Neurobiol Aging. 2014;35:2574-2583 pubmed publisher |
- immunohistochemistry; human; 1:100
| Pócza T, Sebestyen A, Turányi E, Krenacs T, Márk A, Sticz T, et al. mTOR pathway as a potential target in a subset of human medulloblastoma. Pathol Oncol Res. 2014;20:893-900 pubmed publisher |
| Chang P, Wang T, Chang Y, Chu C, Lee C, Hsu H, et al. Autophagy pathway is required for IL-6 induced neuroendocrine differentiation and chemoresistance of prostate cancer LNCaP cells. PLoS ONE. 2014;9:e88556 pubmed publisher |
- immunohistochemistry; rat; 1:200
| Jiang F, Pang X, Niu Q, Hua L, Cheng M, Ji Y. Activation of mammalian target of rapamycin mediates rat pain-related responses induced by BmK I, a sodium channel-specific modulator. Mol Pain. 2013;9:50 pubmed publisher |
- immunohistochemistry - paraffin section; cat; 1:50
| Maniscalco L, Millan Y, Iussich S, Denina M, Sánchez Cespedes R, Gattino F, et al. Activation of mammalian target of rapamycin (mTOR) in triple negative feline mammary carcinomas. BMC Vet Res. 2013;9:80 pubmed publisher |
- immunocytochemistry; human; fig 7
- western blot; human
| Vazquez Martin A, Sauri Nadal T, Menendez O, Oliveras Ferraros C, Cufí S, Corominas Faja B, et al. Ser2481-autophosphorylated mTOR colocalizes with chromosomal passenger proteins during mammalian cell cytokinesis. Cell Cycle. 2012;11:4211-21 pubmed publisher |
| Belounis A, Nyalendo C, Le Gall R, Imbriglio T, Mahma M, Teira P, et al. Autophagy is associated with chemoresistance in neuroblastoma. BMC Cancer. 2016;16:891 pubmed |
| Stelloo S, Sanders J, Nevedomskaya E, de Jong J, Peters D, van Leenders G, et al. mTOR pathway activation is a favorable prognostic factor in human prostate adenocarcinoma. Oncotarget. 2016;7:32916-24 pubmed publisher |
| Li S, Chen C, Lu H, Huang W, Tien W, Lan Y, et al. Phosphorylated p70S6K expression is an independent prognosticator for patients with esophageal squamous cell carcinoma. Surgery. 2015;157:570-80 pubmed publisher |
| Sahin K, Cross B, Sahin N, Ciccone K, Suleiman S, Osunkoya A, et al. Lycopene in the prevention of renal cell cancer in the TSC2 mutant Eker rat model. Arch Biochem Biophys. 2015;572:36-9 pubmed publisher |
| Theiss A, Chafin D, Bauer D, Grogan T, Baird G. Immunohistochemistry of colorectal cancer biomarker phosphorylation requires controlled tissue fixation. PLoS ONE. 2014;9:e113608 pubmed publisher |
| Haddad A, Kapur P, Singla N, Raman J, Then M, Nuhn P, et al. Validation of mammalian target of rapamycin biomarker panel in patients with clear cell renal cell carcinoma. Cancer. 2015;121:43-50 pubmed publisher |
| Bitanihirwe B, Meerang M, Friess M, Soltermann A, Frischknecht L, Thies S, et al. PI3K/mTOR signaling in mesothelioma patients treated with induction chemotherapy followed by extrapleural pneumonectomy. J Thorac Oncol. 2014;9:239-47 pubmed publisher |
| Rojo F, Domingo L, Sala M, Zazo S, Chamizo C, Menendez S, et al. Gene expression profiling in true interval breast cancer reveals overactivation of the mTOR signaling pathway. Cancer Epidemiol Biomarkers Prev. 2014;23:288-99 pubmed publisher |
| Li J, Zhu H, Chen T, Zou L, Wang X, Zhao H, et al. Roles of mTOR and p-mTOR in gastrointestinal stromal tumors. Asian Pac J Cancer Prev. 2013;14:5925-8 pubmed |
| Kumar D, Shankar S, Srivastava R. Rottlerin induces autophagy and apoptosis in prostate cancer stem cells via PI3K/Akt/mTOR signaling pathway. Cancer Lett. 2014;343:179-89 pubmed publisher |
| Komori Y, Yada K, Ohta M, Uchida H, Iwashita Y, Fukuzawa K, et al. Mammalian target of rapamycin signaling activation patterns in pancreatic neuroendocrine tumors. J Hepatobiliary Pancreat Sci. 2014;21:288-95 pubmed publisher |
| Monteiro L, Delgado M, Ricardo S, Garcez F, Do Amaral B, Warnakulasuriya S, et al. Phosphorylated mammalian target of rapamycin is associated with an adverse outcome in oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013;115:638-45 pubmed publisher |
| Leal P, Garcia P, Sandoval A, Letelier P, Brebi P, Ili C, et al. Immunohistochemical expression of phospho-mTOR is associated with poor prognosis in patients with gallbladder adenocarcinoma. Arch Pathol Lab Med. 2013;137:552-7 pubmed publisher |
| Griner S, Joshi J, Nahta R. Growth differentiation factor 15 stimulates rapamycin-sensitive ovarian cancer cell growth and invasion. Biochem Pharmacol. 2013;85:46-58 pubmed publisher |
| Muller J, Ehlers A, Burkhardt L, Sirma H, Steuber T, Graefen M, et al. Loss of pSer2448-mTOR expression is linked to adverse prognosis and tumor progression in ERG-fusion-positive cancers. Int J Cancer. 2013;132:1333-40 pubmed publisher |
| Li S, Huang E, Lu H, Huang W, Yen C, Huang W, et al. Phosphorylated mammalian target of rapamycin expression is associated with the response to chemoradiotherapy in patients with esophageal squamous cell carcinoma. J Thorac Cardiovasc Surg. 2012;144:1352-9, 1359.e1 pubmed publisher |
| Zhan H, Cong L, Zhao Y, Zhang T, Chen G, Zhou L, et al. Activated mTOR/P70S6K signaling pathway is involved in insulinoma tumorigenesis. J Surg Oncol. 2012;106:972-80 pubmed publisher |
| Stemmer K, Perez Tilve D, Ananthakrishnan G, Bort A, Seeley R, Tschop M, et al. High-fat-diet-induced obesity causes an inflammatory and tumor-promoting microenvironment in the rat kidney. Dis Model Mech. 2012;5:627-35 pubmed publisher |
| Murakami A, Gomi K, Tanaka M, Ohyama M, Itani Y, Ishikawa H, et al. Unilateral glomerulocystic kidney disease associated with tuberous sclerosis complex in a neonate. Pathol Int. 2012;62:209-15 pubmed publisher |
| Yoon D, Ryu M, Park Y, Lee H, Lee C, Ryoo B, et al. Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum. Br J Cancer. 2012;106:1039-44 pubmed publisher |
| Walsh S, Flanagan L, Quinn C, Evoy D, McDermott E, Pierce A, et al. mTOR in breast cancer: differential expression in triple-negative and non-triple-negative tumors. Breast. 2012;21:178-82 pubmed publisher |
| Lee D, Do I, Choi K, Sung C, Jang K, Choi D, et al. The expression of phospho-AKT1 and phospho-MTOR is associated with a favorable prognosis independent of PTEN expression in intrahepatic cholangiocarcinomas. Mod Pathol. 2012;25:131-9 pubmed publisher |
| Javle M, Shroff R, Xiong H, Varadhachary G, Fogelman D, Reddy S, et al. Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies. BMC Cancer. 2010;10:368 pubmed publisher |
| Chung J, Hong S, Choi B, Cho H, Yu E, Hewitt S. The expression of phospho-AKT, phospho-mTOR, and PTEN in extrahepatic cholangiocarcinoma. Clin Cancer Res. 2009;15:660-7 pubmed publisher |
